| Development Programs | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
|---|---|---|---|---|---|---|
| VK2735 Subcutaneous(Dual GLP-1/GIP agonist) | Obesity |
|
Phase 3 underway; Phase 1 monthly study planned 3Q25 | |||
| VK2735 Oral (Dual GLP-1/GIP agonist) | Obesity |
|
Phase 2 underway | |||
| Amylin agonist | Obesity |
|
IND Planned 4Q25 | |||
| VK2809 (TRβ Agonist) | MASH |
|
Phase 2b VOYAGE trial successfully completed | |||
| VK0214 (TRβ Agonist) | X-ALD |
|
Phase 1b study demonstrated PoC | |||
| Product/Target | Indication | Phase |
|---|---|---|
| VK2735 Subcutaneous(Dual GLP-1/GIP agonist) | Obesity | Phase 3 underway; Phase 1 monthly study planned 3Q25 |
| VK2735 Oral (Dual GLP-1/GIP agonist) | Obesity | Phase 2 underway |
| Amylin agonist | Obesity | IND Planned 4Q25 |
| VK2809 (TRβ Agonist) | MASH | Phase 2b VOYAGE trial successfully completed |
| VK0214 (TRβ Agonist) | X_ALD | Phase 1b study demonstrated PoC |